Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Academic Article uri icon

Overview

abstract

  • INTRODUCTION: With the use of reduced-intensity conditioning (RIC), early toxicity of allogeneic stem cell transplantation (SCT) has been much reduced. Graft-versus-host disease (GvHD) causes morbidities and mortality. Alemtuzumab is a mAb directed against CD52. When administered prior to transplant, it leads to T-cell depletion. Incorporation of alemtuzumab in RIC results in low rates of GvHD and treatment-related mortality (TRM) in haematological diseases, even in the setting of mismatched-donor transplantation. AREAS COVERED: The use of alemtuzumab for GvHD prophylaxis in SCT. The benefit of alemtuzumab-based conditioning is partially offset by increased disease relapse due to impaired graft-versus-tumor effect (GvT) and by slower immune reconstitution, necessitating special precautions. While GvHD is prevented with alemtuzumab, post-SCT interventions are often required. Most studies find that alemtuzumab-based conditioning results in decreased chronic GvHD and TRM, but also in decreased progression-free survival. Overall survival after 3 - 5 years is usually equivalent and quality of life may be improved because of a lower incidence of sequelae of chronic GvHD. Many aspects of alemtuzumab treatment are under investigation. EXPERT OPINION: Alemtuzumab reduces GvHD and TRM after SCT. Use of alemtuzumab requires awareness and strict management of the risk of opportunistic infections and of an increased risk of disease recurrence.

publication date

  • June 27, 2011

Research

keywords

  • Antibodies, Monoclonal
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Graft vs Host Disease
  • Hematologic Neoplasms
  • Hematopoietic Stem Cell Transplantation

Identity

PubMed Central ID

  • PMC3126913

Scopus Document Identifier

  • 79959889702

Digital Object Identifier (DOI)

  • 10.1038/bmt.2010.308

PubMed ID

  • 21702703

Additional Document Info

volume

  • 11

issue

  • 8